Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Amyris Biotech

Explore full profile

Creates renewable products, focusing on fuels and chemicals

Emeryville, United StatesFounded 2003Chemicals
Valuation $532M Market cap · 2010
Revenue $270M Latest reported FY
Total funding $100–500M Disclosed equity funding

About Amyris Biotech

Founded in 2003 by a group of scientists from the University of California, Berkeley, including Jay Keasling, Jack D. Newman, Keith Kinkead Reiling, and Neil Renninger, Amyris, Inc. began with a focus on applying synthetic biology to address global challenges. An early significant achievement, supported by a grant from the Bill & Melinda Gates Foundation, was engineering yeast to produce artemisinic acid, a precursor to an effective anti-malarial drug, making the treatment more accessible. Keasling, a professor of chemical and bioengineering, is considered a leading authority in synthetic biology, and his work has been foundational to the company's trajectory.

Read full description

The company's core business revolves around its proprietary Lab-to-Market™ technology platform, which uses genetically engineered microorganisms, primarily yeast, to convert plant-based sugars from sugarcane into a wide array of molecules through fermentation. This process serves as a sustainable alternative to traditional manufacturing methods that often rely on petrochemicals or scarce natural resources. Amyris operates as both a business-to-business (B2B) ingredient supplier and a direct-to-consumer (D2C) brand portfolio manager. For its B2B segment, the company develops and manufactures specialty ingredients for the flavors and fragrances, cosmetics, pharmaceuticals, and nutraceuticals markets, selling them to large corporations. Its D2C model involved creating and marketing its own consumer brands, such as Biossance (skincare) and JVN (haircare), which utilized its bio-manufactured ingredients.

Amyris's product portfolio is diverse, stemming from its flexible production platform. A cornerstone ingredient is squalane, a high-performance emollient traditionally sourced from shark livers, which Amyris produces from sugarcane, thereby offering a sustainable alternative for the cosmetics industry. Another key product is hemisqualane, a plant-based silicone alternative. The company has successfully commercialized over a dozen molecules, including a zero-calorie sweetener (Reb M) and ingredients for fragrances. In early 2023, the Swiss fragrance and cosmetic ingredient maker Givaudan acquired a significant portion of Amyris's cosmetic ingredients portfolio, including squalane and hemisqualane, in a deal that included a long-term manufacturing agreement.

Despite its scientific and commercial successes, the company faced significant financial challenges. After years of operating at a loss, Amyris filed for Chapter 11 bankruptcy protection in August 2023. The restructuring plan involved divesting its portfolio of consumer brands to focus on its core competencies: research and development, and the commercialization of sustainable ingredients for its B2B clients. As part of this transition, long-time CEO John Melo stepped down in June 2023, and Han Kieftenbeld was appointed as interim CEO. The company successfully emerged from bankruptcy in May 2024, with Kathy Fortmann installed as the new CEO to lead a strategy focused on B2B customers.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2003
Headquarters
Emeryville, United States
Listing
IPO 2010
Employees
991
Open positions
26
Dealroom signal
69.0/100
Industry
Chemicals
Sector
Chemicals, Biotechnology, Chemistry, Nutrition, Synthetic Biology, Spinout, Biotech and Pharma, Fermentation, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
b2b, b2c
Investment activity
3 companies, latest Sep 2021
Capital deployed
Preferred round
ACQUISITION

Latest news

Press, funding announcements and product moves mentioning Amyris Biotech.

See all news

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO DEBTDebt Nov 2021 $400M Undisclosed
POST IPO EQUITYOther financing Apr 2021 $300M Undisclosed
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026 $270M 0%
2025 $270M 0%
2024 $270M 0%
2023 $270M 0%
2022 $270M -21%
2021 $342M +97.4%
2020 $173M
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Amyris Biotech website traffic

Latest recorded traffic for Amyris Biotech is 5.7K monthly website visits, down 3.4% over the last three months. Amyris Biotech's team grew 0.3% over the past year.

Latest monthly visits5.7K 3-month web change-3.4% 1-year team growth+0.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • National Institutes of Health

Series A4 investors entered at this stage

Series B and later5 investors entered at this stage

  • P&G Ventures
  • Temasek
  • DSM
  • Wei-Wu He
  • John Doerr

Other known investors1 additional known investor

  • University of California, Berkeley
Team profiled 87 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
11 countries with
team presence
🇧🇷 Brazil52.9%
🇺🇸 United States42.3%
🇵🇹 Portugal1.7%
🇬🇧 United Kingdom1%
🇮🇳 India0.6%
Top 5 of 11 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Amyris Biotech on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Amyris Biotech’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.